Minimal impact on the resistome of children in Botswana after azithromycin treatment for acute severe diarrhoeal disease

Mass distribution of azithromycin has been recommended to reduce under-five mortality rates in certain countries in sub-Saharan Africa. Additionally, antibiotic treatment of children with bacterial gastroenteritis holds promise for the prevention of mortality and the optimization of linear growth. However, mass administration and imprudent prescription of antibiotics can select for antibiotic-resistant bacteria in the gut microbiota of children. The long-term implications of this selection are unknown and worrisome. Our previous randomized controlled trial of children hospitalized with severe acute diarrhoeal disease in Botswana evaluated the efficacy of a test-and-treat strategy. Participants randomized to the intervention group who were found to have enterotoxigenic or enteropathogenic E. coli, Shigella, or Campylobacter detectable by a rapid qualitative multiplex PCR assay at admission were treated with azithromycin and those randomized to the control group received supportive treatment (usual care). Stool samples were collected at baseline and at 60 days. In this current study, DNA from 136 stool samples was enriched and sequenced to detect changes in the resistome, otherwise known as the collection of antibiotic resistance genes. At baseline, the gut microbiota of these children contained a diverse complement of azithromycin resistance genes that increased in prevalence in both treatment groups by 60 days. Certain 23S rRNA methyltransferases were associated with other resistance genes and mobile genetic elements, highlighting the potential for the transfer of macrolide resistance in the gut microbiome. There were other minor changes in non-azithromycin resistance genes; however, the trends were not specific to the antibiotic-treated children. In conclusion, a three-day azithromycin treatment for diarrhoea for young children in Botswana did not increase the prevalence of azithromycin-specific antibiotic resistance genes at 60 days. The gut microbiota of these children appeared primed for macrolide resistance, and repeated exposures may further select resistant bacteria.

[1]  D. Operario,et al.  Azithromycin for bacterial watery diarrhea: A reanalysis of the AntiBiotics for Children with severe Diarrhea (ABCD) trial incorporating molecular diagnostics. , 2023, The Journal of infectious diseases.

[2]  Danny W. Wilson,et al.  Targeting malaria parasites with novel derivatives of azithromycin , 2022, Frontiers in Cellular and Infection Microbiology.

[3]  Damion M. Dooley,et al.  CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database , 2022, Nucleic Acids Res..

[4]  G. Kang,et al.  Frequency of bystander exposure to antibiotics for enteropathogenic bacteria among young children in low-resource settings , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Amogelang R. Raphenya,et al.  Capturing the antibiotic resistome of preterm infants reveals new benefits of probiotic supplementation , 2022, Microbiome.

[6]  Joycelyne E Ewusie,et al.  Optimising the management of childhood acute diarrhoeal disease using a rapid test-and- treat strategy and/or Lactobacillus reuteri DSM 17938: a multicentre, randomised, controlled, factorial trial in Botswana , 2022, BMJ Global Health.

[7]  Hao Chung The,et al.  Dynamic of the human gut microbiome under infectious diarrhea , 2022, Current opinion in microbiology.

[8]  Alan D. Lopez,et al.  Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.

[9]  C. Sudfeld,et al.  Effect of 3 Days of Oral Azithromycin on Young Children With Acute Diarrhea in Low-Resource Settings , 2021, JAMA network open.

[10]  Q. Bassat,et al.  Pathogens Associated With Linear Growth Faltering in Children With Diarrhea and Impact of Antibiotic Treatment: The Global Enteric Multicenter Study , 2021, The Journal of infectious diseases.

[11]  T. Mizutani,et al.  Gut microbiota signature of pathogen-dependent dysbiosis in viral gastroenteritis , 2021, Scientific Reports.

[12]  L. Worden,et al.  Gut Resistome of Preschool Children After Prolonged Mass Azithromycin Distribution: A Cluster-randomized Trial , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  M. Lipsitch,et al.  Selection of Macrolide and Non-Macrolide Resistance with Mass Azithromycin Distribution: A Community-Randomized Trial , 2020, The New England journal of medicine.

[14]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[15]  J. Stearns,et al.  Persistence of Suspected Probiotic Organisms in Preterm Infant Gut Microbiota Weeks After Probiotic Supplementation in the NICU , 2020, Frontiers in Microbiology.

[16]  R. Haque,et al.  Effect of Water, Sanitation, Handwashing, and Nutrition Interventions on Enteropathogens in Children 14 Months Old: A Cluster-Randomized Controlled Trial in Rural Bangladesh , 2020, The Journal of infectious diseases.

[17]  Y. Hooda,et al.  Mass azithromycin administration: considerations in an increasingly resistant world , 2020, BMJ Global Health.

[18]  Chaojie Yang,et al.  A new plasmid carrying mphA causes prevalence of azithromycin resistance in enterotoxigenic Escherichia coli serogroup O6 , 2020, BMC Microbiology.

[19]  Amogelang R. Raphenya,et al.  Capturing the Resistome: a Targeted Capture Method To Reveal Antibiotic Resistance Determinants in Metagenomes , 2019, Antimicrobial Agents and Chemotherapy.

[20]  E. Chow,et al.  Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution , 2019, Nature Medicine.

[21]  B. Godman,et al.  Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications , 2019, Expert review of anti-infective therapy.

[22]  T. Doan,et al.  Macrolide Resistance in MORDOR I: A Cluster-Randomized Trial in Niger , 2019, The New England journal of medicine.

[23]  K. Tapela,et al.  Isolation and antibiotic resistance profiles of bacteria from influent, effluent and downstream: A study in Botswana , 2019, African Journal of Microbiology Research.

[24]  E. Mworozi,et al.  Barriers to effective uptake and provision of immunization in a rural district in Uganda , 2019, PloS one.

[25]  D. Jannat-Khah,et al.  Azithromycin and Childhood Mortality in Africa. , 2018, New England Journal of Medicine.

[26]  Mark A. Miller,et al.  Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study , 2018, The Lancet. Global health.

[27]  Holly N. Dentz,et al.  Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial , 2018, The Lancet. Global health.

[28]  T. Clasen,et al.  Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial , 2018, The Lancet. Global health.

[29]  M. Loeb,et al.  Rapid enteric testing to permit targeted antimicrobial therapy, with and without Lactobacillus reuteri probiotics, for paediatric acute diarrhoeal disease in Botswana: A pilot, randomized, factorial, controlled trial , 2017, PloS one.

[30]  Mika Shigematsu,et al.  Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Infectious diseases.

[31]  C. Gomes,et al.  Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin , 2016, Critical reviews in microbiology.

[32]  W. van Schaik The human gut resistome , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[33]  Lawrence A. David,et al.  Gut Microbial Succession Follows Acute Secretory Diarrhea in Humans , 2015, mBio.

[34]  Carla J. Davidson,et al.  Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age , 2015, The ISME Journal.

[35]  G. Verleden,et al.  Azithromycin: mechanisms of action and their relevance for clinical applications. , 2014, Pharmacology & therapeutics.

[36]  Mihai Pop,et al.  Diarrhea in young children from low-income countries leads to large-scale alterations in intestinal microbiota composition , 2014, Genome Biology.

[37]  J. Kuehl,et al.  The Gut as Reservoir of Antibiotic Resistance: Microbial Diversity of Tetracycline Resistance in Mother and Infant , 2011, PloS one.

[38]  D. Relman,et al.  Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation , 2010, Proceedings of the National Academy of Sciences.

[39]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[40]  P. J. Hooper,et al.  Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. , 2019, The Lancet. Infectious diseases.

[41]  I. Kasvosve,et al.  The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management , 2018, Therapeutic advances in infectious disease.